TransMedics Group, Inc. 8-K

What Happened

• TransMedics Group, Inc. filed an 8-K (dated Jan 8, 2026; filed Jan 12, 2026) announcing it entered a lease with BioMed Realty for ~498,286 sq ft at 188 Assembly Park Drive, Somerville, MA to serve as its new headquarters and R&D/manufacturing campus. The Lease commences Jan 8, 2026 (Delivery Date) and the Company expects to occupy the new HQ on or before Jan 1, 2028, replacing its Andover headquarters.
• The Company also acquired two adjacent parcels in Somerville on Jan 8, 2026 from BRE-BMR entities for $15.0 million each (plus related costs).

Key Details

• Premises: ~498,286 sq ft at 188 Assembly Park Drive, Somerville, MA.
• Lease start/delivery date: January 8, 2026; expected move-in by Jan 1, 2028.
• Rent: Initial annual base rent ≈ $23.9 million, with 2% annual increases; Rent Commencement Date is the later of Jan 1, 2028 or 24 months after term commencement (no later than Feb 1, 2028).
• Term/options: Initial term of 192 months (16 years) from Rent Commencement Date; two consecutive 10‑year extension options and a six‑month extension option.
• Other financials: Company responsible for pro rata operating/tax expenses (estimated ≈100%); security deposit provided via letter of credit ≈ $18 million.
• Land purchases: Two parcels purchased for $15.0M each (total $30.0M before closing costs/taxes).

Why It Matters

• This is a large, long‑term real estate commitment that will centralize TransMedics’ headquarters, R&D, manufacturing and related operations in Somerville. The lease creates a sizeable future cash obligation (initial base rent ~ $23.9M/year with annual increases) and operating expense exposure that investors should consider when assessing future cash flow needs.
• The ~$18M letter of credit and the ~$30M of land purchases increase near‑term liquidity and capital deployment considerations. The filing does not report changes to revenues or operating results; it discloses contractual and capital commitments that may affect cash position and lease accounting in future financial reports.
• The 8-K includes standard forward‑looking statement cautions; investors should review the full lease (Exhibit 10.1) and the company’s subsequent SEC filings for additional detail.